Xenon Pharmaceuticals (XENE)
(Real Time Quote from BATS)
$37.46 USD
-0.30 (-0.79%)
Updated Sep 19, 2025 11:46 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
XENE 37.46 -0.30(-0.79%)
Will XENE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for XENE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XENE
Why Is Xenon Pharmaceuticals (XENE) Up 4.2% Since Last Earnings Report?
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus
XENE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
Other News for XENE
XENE rises 2.89% on September 18, leaving the technical picture intact
Crossed Above 200 Day Moving Average appears for XENE after 2.92% move
COMMODORE CAPITAL LP Acquires Significant Stake in Terns Pharmaceuticals Inc
Jefferies Reaffirms Their Buy Rating on Xenon (XENE)
XENE forms Non-ADX 1,2,3,4 Bullish on September 16